While the specificity of myoferlin targeting has already been assessed previously in pancreatic cancer cells (Rademaker et al, 2022), we validated that WJ460 indeed impaired ECM production dose-dependently in myCAFs, in accordance with MYOFKD (Fig. EV7B–F). This evidence concerns the gene MYOF and pancreatic neoplasm.